High Growth Tech Stocks To Watch In October 2024

In This Article:

As global markets navigate the complexities of escalating Middle East tensions and robust U.S. job growth, investors are closely monitoring the performance of key indices like the S&P 500 and Nasdaq Composite, both showing significant year-to-date gains despite geopolitical uncertainties. In this environment, identifying promising high-growth tech stocks involves looking for companies that demonstrate resilience and adaptability to market shifts, coupled with innovative capabilities that align with evolving economic conditions.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

Clinuvel Pharmaceuticals

22.32%

27.42%

★★★★★★

Sarepta Therapeutics

23.58%

44.11%

★★★★★★

TG Therapeutics

28.39%

43.54%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Medley

24.98%

30.36%

★★★★★★

Seojin SystemLtd

33.39%

49.13%

★★★★★★

KebNi

34.75%

86.11%

★★★★★★

Mental Health TechnologiesLtd

27.88%

79.61%

★★★★★★

Adveritas

57.98%

144.21%

★★★★★★

UTI

114.97%

134.60%

★★★★★★

Click here to see the full list of 1278 stocks from our High Growth Tech and AI Stocks screener.

We're going to check out a few of the best picks from our screener tool.

Vericel

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vericel Corporation is a commercial-stage biopharmaceutical company focused on the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America, with a market cap of $2.13 billion.

Operations: Vericel generates revenue primarily from its biotechnology segment, amounting to $214.52 million. The company operates within the sports medicine and severe burn care sectors in North America.

Vericel's recent FDA approval for MACI Arthro, a less invasive knee repair technique, underscores its innovative edge in biotech. This advancement not only expands the treatment's label but also targets an additional 20,000 patients annually within a $3 billion market. Coupled with strategic expansions to include high-volume surgeons, Vericel is poised to capture significant market share. Financially, the company has shown resilience with a 22% year-over-year revenue increase in Q2 2024 and is projected to sustain robust growth with earnings expected to surge by 51.6% annually. These developments reflect Vericel’s strong positioning for future growth amidst evolving medical technologies and increasing demand for minimally invasive procedures.